Celldex Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Anthony S. Marucci (President and CEO) and Sam Martin (Senior Vice President and CFO) certified on August 6, 2026 that the Q2 2026 10-Q contains no untrue material statements, fairly presents financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud involving management were disclosed.
Why this rating
Routine Sarbanes-Oxley certifications. Standard quarterly filing requirement; no operational, financial, or strategic changes disclosed. No transaction, guidance revision, or control weakness reported.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.